| Pharmaceutical Information |
| Drug Name |
Rasagiline mesylate |
| Drug ID |
BADD_D01916 |
| Description |
Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases. |
| Indications and Usage |
For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa. |
| Marketing Status |
approved |
| ATC Code |
N04BD02 |
| DrugBank ID |
DB01367
|
| KEGG ID |
D02562
|
| MeSH ID |
C031967
|
| PubChem ID |
3052775
|
| TTD Drug ID |
D06OMW
|
| NDC Product Code |
0378-1271; 57741-1900; 23155-746; 68546-229; 65035-133; 57741-2000; 65015-775; 55111-900; 66039-878; 23155-747; 0378-1270; 68546-142; 82245-0114 |
| UNII |
LH8C2JI290
|
| Synonyms |
rasagiline | N-2-propynyl-1-indanamine | AGN 1135 | AGN-1135 | TVP 1022 | TVP1022 | TVP-1022 | N-propargyl-1-aminoindan mesylate | rasagiline hydrochloride | TVP 101 | TVP-101 | 2,3-dihydro-N-2-propynyl-1H-inden-1-amine-(1R)-hydrochloride | Azilect |
|
| Chemical Information |
| Molecular Formula |
C13H17NO3S |
| CAS Registry Number |
161735-79-1 |
| SMILES |
CS(=O)(=O)O.C#CCNC1CCC2=CC=CC=C12 |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
